科学图书馆
-
Polymer-based or Polymer-free Stents in Patients at High Bleeding RiskS Windecker, A Latib, the ONYX ONE Investigators et al. -
Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trialSong YB, Gwon HC, Hahn JY et al.
-
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelorM Verdoiaab, M Nardinb, R Gioscia et al.
-
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trialFeres F, Costa RA, OPTIMIZE Trial Investigators.
-
A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor SignalingBAT Rodriguez, A Bhan, A Beswick et al.
-
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Leonardi S, Franzone A, Piccolo R et al.
-
Impact of bleeding during dual antiplatelet therapy in patients with coronary artery diseaseY-C Tung, C-T Kuo, C-J Chang et al.
-
Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical TrialR Mehran, J Chandrasekhar, P Urban et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
